Remove Drug Pricing Remove Events Remove Vaccines
article thumbnail

Locked in a federal stalemate, states take PBM reform into their own hands

PharmaVoice

Known as the negotiators between health plans, pharmacies and drug companies, pharmacy benefit managers are currently entangled in a national conversation about reform. The pharma industry has long blamed PBMs for rising drug prices, pointing to opaque rebate and profit structures , and proposed policy shifts could take them to task.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmacy Policy Updates for June 2025

Pharmacy Times

According to Trump, patients could see cost reductions of 30% to 80%, but experts question the feasibility and practicality of implementing such a policy within the complex United States drug pricing and supply system. Kennedy Jr, is permitted to develop a new rule that ties American drug prices to those of other nations.

article thumbnail

Building Intelligent Pharma Supply Chain Management with Real-World Data

Pharmaceutical Commerce

This is especially critical for temperature-sensitive biologics and vaccines, where maintaining proper storage conditions ensures product viability and regulatory compliance. In some cases, these events might be entirely unpredictable, forcing them to adapt product strategies with little to no advanced preparation.

article thumbnail

Sanofi to Begin Globally Shipping Beyfortus Ahead of RSV Season

Pharmaceutical Commerce

and outperformed maternal vaccines in public health programs. Vaccines to treat RSV normally start in early fall, and having these additional shipments in advance is expected to give healthcare providers (HCPs) an additional assurance and confidence. Sanofi and AstraZeneca have tripled production capacity to meet growing demand.

article thumbnail

Will pharma finally score a policy win for 340B?

PharmaVoice

The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight. The 340B Drug Pricing Program has long been a contentious issue for pharma. Please let us know if you have feedback. By Kelly Bilodeau A day in the life of GSK’s U.S.

Hospitals 215
article thumbnail

MHRA approves needle-free adrenaline nasal spray for anaphylaxis

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out?